Literature DB >> 2454258

The sites of catabolism of murine monomeric IgA.

Z Moldoveanu1, J M Epps, S R Thorpe, J Mestecky.   

Abstract

The tissue sites of monomeric IgA (mIgA) catabolism were determined in a BALB/c mouse model. Mouse mIgA myeloma proteins were labeled either by direct iodination or by coupling the residualizing label, dilactitol-125I-tyramine (125I-DLT) to the proteins; catabolites from protein labeled with 125I-DLT accumulate at the site of protein degradation, allowing identification of the tissue and cellular sites involved in catabolism of the protein. The circulating half-lives of 125I- and 125I-DLT-mIgA were the same. The distribution of radioactivity in tissues was measured at 1, 3, 24, and 96 h after iv. injection of 125I-DLT-labeled mIgA, dimeric IgA (dIgA), IgG, or mouse serum albumin. The greatest uptake of 125I-DLT-mIgA was attributable to the liver. This organ accounted for more internal catabolism of mIgA than all other tissues combined. In contrast, 125I-DLT-IgG was catabolized equally in skin, muscle, and liver. These data indicate that, in mice, the liver is the major site of mIgA catabolism. To determine the cell types involved, collagenase digestion was used to isolate parenchymal and non-parenchymal cells from perfused liver of animals injected with 125-DLT-mIgA. Most of the radioactivity was associated with the hepatocyte fraction, even though both cell types showed uptake of 125I-DLT-mIgA. Inhibition studies, with asialofetuin and mouse IgA demonstrated that the uptake of mIgA by liver cells was mediated primarily by the asialoglycoprotein receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454258

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

2.  Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies.

Authors:  M Tomana; J Novak; B A Julian; K Matousovic; K Konecny; J Mestecky
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 3.  Glycosylation of IgA1 and pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Jiri Mestecky; Matthew B Renfrow
Journal:  Semin Immunopathol       Date:  2012-03-21       Impact factor: 9.623

4.  Catabolism of hirudin and thrombin-hirudin complexes in the rat.

Authors:  J Bichler; J W Baynes; S R Thorpe
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

5.  A fluorescent residualizing label for studies on protein uptake and catabolism in vivo and in vitro.

Authors:  J L Maxwell; L Terracio; T K Borg; J W Baynes; S R Thorpe
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

6.  Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiography.

Authors:  S Demignot; M V Pimm; S R Thorpe; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 7.  IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Milan Tomana; Jiri Mestecky
Journal:  Semin Nephrol       Date:  2008-01       Impact factor: 5.299

8.  Kupffer cell depletion in vivo results in clearance of large-sized IgA aggregates in rats by liver endothelial cells.

Authors:  W M Bogers; R K Stad; D J Janssen; F A Prins; N van Rooijen; L A van Es; M R Daha
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

9.  A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

Authors:  Gerard Ja Rouwendal; Miranda M van der Lee; Saskia Meyer; Karli R Reiding; Jan Schouten; Guy de Roo; David F Egging; Jeanette Hw Leusen; Peter Boross; Manfred Wuhrer; Gijs F Verheijden; Wim H Dokter; Marco Timmers; Ruud Ubink
Journal:  MAbs       Date:  2015-10-06       Impact factor: 5.857

10.  Non-invasive detection of protein metabolism in vivo by n.m.r. spectroscopy. Application of a novel 19F-containing residualizing label.

Authors:  A Daugherty; N N Becker; L A Scherrer; B E Sobel; J J Ackerman; J W Baynes; S R Thorpe
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.